Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - antineoplastilised ained - koerad - ravi mitte-resectable koer mast-rakkude kasvajad (klass 2 või 3), kellel on kinnitatud muteerunud c-kit türosiin-kinase retseptori.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitinib mesilate - amüotroofiline lateraalskleroos - antineoplastilised ained - ravi lateraalskleroosi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitinib mesilate - mastotsütoos - antineoplastilised ained - ravi mastocytosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitiniib - pankrease neoplasmid - protein kinase inhibiitorid - ravi mitte resectable lokaalselt kaugelearenenud või metastaatiline pankrease vähk.

Euroopa Liit - eesti - EMA (European Medicines Agency)

masitiniib - seedetraktist esinevad stromaal-kasvajad - protein kinase inhibiitorid - ravi unresectable ja/või metastaatilise pahaloomulise seedetrakti stromal kasvaja (pÕhilised).

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Eesti - eesti - Ravimiamet

stada arzneimittel ag - aksitiniib - õhukese polümeerikattega tablett - 1mg 28tk; 1mg 14tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - aksitiniib - õhukese polümeerikattega tablett - 5mg 14tk; 5mg 56tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - aksitiniib - õhukese polümeerikattega tablett - 3mg 14tk